Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05581004 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Genentech.

Recruiting
Registry status
Phase 1
Development phase
450
Enrollment target
20
Study locations

NCT05581004 is a Phase 1 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by Genentech. The registered enrollment target is 450 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05581004, a Phase 1 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by Genentech.

RECRUITING
Registry status
Phase 1
Development phase
450 participants
Enrollment target
20
Study locations

Study Summary

This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), melanoma, triple-negative breast cancer (TNBC), esophageal cancer, gastric cancer, cervical cancer, colorectal cancer (CRC), urothelial carcinoma (UC), clear cell renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Participants will be enrolled in 2 stages: dose escalation and dose expansion.

Conditions Studied

Colorectal Cancer Melanoma Gastric Cancer Cervical Cancer Esophageal Cancer Urothelial Carcinoma NSCLC HNSCC Locally Advanced or Metastatic Solid Tumors TNBC

Interventions

  • DRUG Pembrolizumab
  • DRUG Atezolizumab
  • DRUG RO7502175

Study Locations (20)

Other

  • UZ Antwerpen - Edegem
  • CHU de Liège - Herstal
  • GasthuisZusters Antwerpen - Wilrijk

Tennessee

  • The West Clinic - Memphis (Union Ave) - Germantown
  • SCRI Oncology Partners - Nashville

Ontario

  • Ottawa Hospital Regional Cancer Centre - Ottawa
  • Princess Margaret Cancer Centre - Toronto

California

  • Stanford University - San Francisco

Colorado

  • University Of Colorado - Aurora

Florida

  • Florida Cancer Specialists - Sarasota - Sarasota

Georgia

  • Winship Cancer Institute - Atlanta

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 450 participants
Start Date 2022-10-20
Est. Completion 2027-02-28
Phase Phase 1

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05581004

The ClinicalTrials.gov registry entry for NCT05581004 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT05581004 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Tennessee, Ontario.

Frequently Asked Questions

What is clinical trial NCT05581004 about?

NCT05581004 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors". This is a first-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of RO7502175 when administered as a single agent and in combination with atezolizumab or pembrolizumab in adult participants with locally advanced or metastatic solid tumors, including...

What is the current status of trial NCT05581004?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 450 participants. The study started on 2022-10-20. Estimated completion is 2027-02-28.

What conditions does trial NCT05581004 study?

This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Gastric Cancer, Cervical Cancer, Esophageal Cancer.

What interventions are being tested in trial NCT05581004?

The interventions under investigation include: Pembrolizumab (DRUG), Atezolizumab (DRUG), RO7502175 (DRUG).

Who is sponsoring clinical trial NCT05581004?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05581004 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.